Program
Lamivudine
Also written as “Lamivudine/Zidovudine”, “Lamivudine (3TC)” and “lamivudine”.
Its studies are mostly in HIV Infections · Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · Infections · Hepatitis B, led by 5 companies.
Drug pageLamivudine: every studyMany companies study it; this page follows only the 49 they lead. All 239 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKlineits history only | 352 open or running | phase 4since Feb 15, 2000 | Nov 2, 1999 | Sep 14, 2032phase 3 · NCT07393659 |
| Bristol-Myers Squibbits history only | 70 open or running | phase 4since Jun 27, 2005 | Nov 2, 1999 | none ahead |
| Abbott | 40 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| Dupont Merckits history only | 20 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
| triangle-pharmaceuticalsits history only | 10 open or running | phase 3since Nov 2, 1999 | Nov 2, 1999 | none ahead |
Also a collaborator on its studies: PPD Development, LP and Dupont Applied Biosciences.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Abbott only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 2, 1999First study: phase 3 study in HIV InfectionsFirst studyNCT00004583 · 660 enrolled · United States, Australia, Austria and more
- May 29, 2002Phase 2 study in HIV InfectionsNCT00038220 · 40 enrolled · United States
- Aug 15, 2002Phase 2 study in HIV InfectionsNCT00043953 · 30 enrolled · United States, Canada
- Sep 13, 2005Phase 3 study in HIV InfectionsNCT00234923 · 138 enrolled
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
All 4 Abbott leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT00234923HIV Infections | 3 | Completed | Feb 2007 | 138 |
| NCT00043953HIV Infections · United States, Canada | 2 | Completed | 30 | |
| NCT00038220HIV Infections · United States | 2 | Completed | 40 | |
| NCT00004583HIV Infections · United States, Australia, Austria and more | 3 | Completed | 660 |
How it is read
Names in the registry
- “Lamivudine”, 35 entries
- “Lamivudine/Zidovudine”, 6 entries
- “Lamivudine (3TC)”, 4 entries
- “lamivudine”, 3 entries
- “DTG/3TC”, 2 entries
Conditions, from the studies’ own filings
- HIV Infections, 53 studies
- Acquired Immunodeficiency Syndrome, 8 studies
- Hepatitis B, Chronic, 6 studies
- Infections, 4 studies
- Hepatitis B, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.